L2-1

........10........20........30........40........50........60........70........80........90.......100.......110.......120.......130.......140.......150.......160.......170.......180.......190.......200.......210.......220.......230.......240.......250.......260.......270.......280.......290.......300... MLARRRFLQFSGAAVASSLALPLLARAAGKTAASAPTDAALTAATDFAALEKAVRGRFGVTLLDTASGRRIGHRQDERFPMCSTFKSVLAATVLSQAERQPALLDTRVPVRDADLLSHAPVTRRHAGKDMTVRDLCRATIITSDNTAANLLFGVVGGPPAVTAFLRSIGDAVSRTDRLEPELNSFAKGDPRDTTTPAAMAATLQRVVLGEVLQLASRQQLADWLIDNETGDACLRAGLGKLWRVRDKTGSNGEDARNDIAVLWPVAGGAPWVLTAYLQAGAISYEQRATVLAQVGRIADRLIG

L2-2	..............................AT.N......I...S........CA..L.............................M...........M.....R....GE......................................................AS..T...S......................................P..........................R...G...........................................S..............	93.07 %
L2-3	......V........................T................T....CA..L.........................................R..................................................................TS......S.....................G................P..........................R...G..........................................................	95.38 %
L2-4	...........A..................AT.N......I...S........CA..L.............................M...........M.....R....GE......................................................AS..T...S......................................P..........................R...G...........................................S..............	92.74 %
L2-20	..............................AS.R...E..I.T.N......M.CA..L............L................M...........M.....R..........T.................................................AS......S...........E.............M........D...P......S...................R...G...................LS.................N....G..............	90.10 %
L2-28	...................V.........APTRA...E..I............CA..L..S.........V................M...........ARP...R............................................................AS..T...S...........E...........I.M...........RP.................E........R...G...........................................M..............	89.77 %
L2-43	...............................T.N.....T.............CA..L............F................M...........T..................................................................AS......S...........E..........................P..........................R...G...................L...T.................Q.V.............E	93.07 %
L2-47	..............A...............AS.R...E..I.T.N......M.CA..L............L................M...........A.....R.M...............................V..........................AS..T...S......M....E......................D...P......S...................R...G...................LS.............S...N....G..............	88.78 %
L2-49	..............................AT.N......I...S........CA..L.............................M...........T.....R....GE......................................................AS..T...S......................................P..........................R...G...........................................S..............	93.07 %
L2-54	...........A..................AT.N......I...S........CA..L.............S...............M...........M.....R....GE......................................................AS..T...S......................................P..........................R...G...........................................S..............	92.41 %
L2-79	............................AA.TTAT.A...IS...........CA..L............V................M...........A.....R.....E......................................................AS..T...S......M.R..E.............GS.......Q...P..........................R...G...................R............R..Q.....Q.A..............	88.45 %

Last updated: January 08, 2024.

If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.

The development of the BLDB database is funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).

Contact: contact@bldb.eu

Live statistics (since December 3rd, 2023)